CDI scientist, colleagues author review of global burden of fungus Candida auris
Peer-Reviewed Publication
Updates every hour. Last Updated: 29-Dec-2025 23:11 ET (30-Dec-2025 04:11 GMT/UTC)
The fungal species Candida auris is spreading across the globe, and gaining in virulence - but there are strategies available and underway to combat the invasive and drug resistant germ, according to a new review by a Hackensack Meridian Center for Discovery and Innovation (CDI) scientist and colleagues.
China has moved from patchy, post-crisis biosafety rules to a unified legal regime anchored by the 2020 Biosecurity Law, yet fragmentation, weak risk intelligence and poor inter-agency coordination still leave gaps that could be exploited by novel pathogens, synthetic biology or geopolitical tension. Historical review shows three phases: 1949-2002 built basic disease reporting and plant-quarantine systems but relied on paper records; 2003-2019 introduced internet-based surveillance, BSL-3/4 laboratories and alignment with WHO’s International Health Regulations after the SARS shock; 2020-present elevated biosafety to national-security status, enacted the Biosecurity Law and poured funds into diagnostics, vaccines and bio-economic R&D during COVID-19. These steps created the skeleton of a modern system, but four structural weaknesses persist: strategic plans lack operational road-maps and AI-enabled foresight; the legal framework offers no clear dispute-resolution or accountability mechanisms; organisational silos among health, agriculture, science and military agencies hamper horizontal coordination; and public awareness plus professional training remain patchy, weakening compliance culture.
The integration of PD-1 inhibitors into standard chemotherapy and radiotherapy regimens has revolutionized nasopharyngeal carcinoma treatment, yet only a minority of patients achieve durable responses, creating an urgent need for reliable biomarkers that can predict immunotherapy benefit. Recent investigations have identified multiple candidate predictors spanning both the tumor microenvironment and macroenvironment, ranging from tumor-intrinsic factors like PD-L1 expression and Epstein-Barr virus DNA levels to systemic indicators including peripheral blood cell counts and circulating cytokines. These biomarkers reflect the complex interplay between tumor biology, host immunity, and environmental factors that ultimately determine treatment outcomes.